Bristol Myers Squibb presents new data showing effect of early Zeposia (ozanimod) treatment in improving and preserving cognitive function in people with Relapsing Multiple Sclerosis. On June 24th, Bristol Myers Squibb presented results of the DAYBREAK open-label extension trial at the 8th European Academy of Neurology Congress in Vienna, Austria. New post-hoc analyses from the Zeposia (ozanimod) Phase 3…
Category: MS
Aubagio study: no disease activity after 2 years
More than half (58% )of the people with multiple sclerosis (MS) treated with Aubagio (teriflunomide) showed no evidence of disease activity after two years on treatment, according to an Italian study. The study, “Evolution of teriflunomide use in multiple sclerosis: A real-world experience,” was published in the Journal of the Neurological Sciences. Aubagio is an oral disease-modifying therapy that has been…
Kesimpta®▼(ofatumumab): No increased risk of severe COVID-19 infections for adults with RRMS
• Novartis announces that the peer-reviewed journal Neurology and Therapy1 has published new data on COVID-19 infections in people living with relapsing remitting multiple sclerosis (RRMS) treated with Kesimpta® (ofatumumab) • A very small proportion (1.5%) of those fully vaccinated and treated with ofatumumab developed COVID-19. Despite being fully or partially vaccinated all patients with…
Data support body of evidence for ocrelizumab
Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) data on 4th April 2022 that show its benefit on disease progression and cognitive outcomes in primary progressive multiple sclerosis (PPMS) and secondary progressive MS (SPMS). Separate analyses on treatment disparities among newly diagnosed patients with MS by race and ethnicity were presented at the…
Ublituximab trials in Multiple Sclerosis
TG Therapeutics, Inc. announced data from the ULTIMATE I & II Phase 3 trials evaluating ublituximab in patients with relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology (#AAN2022) annual meeting, 2-7 April 2022 in Washington, USA. Highlights of the presentations are outlined below. We are pleased to present additional analyses from…
Data from Phase III Trial “SPI2” for Treatment of Progressive MS
News from MedDay Pharma
EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
News from Novartis on the EU approval of Mayzent (siponimod) for adult patients with SPMS with active disease
Ocrelizumab (Ocrevus®) accepted for use in PPMS within NHS Scotland
Industry news from Roche
Creating clinical leaders, transformation pioneers and innovation specialists: because change starts from the ground up
Those of us in the room have the power we need to fundamentally improve the quality of multiple sclerosis (MS) care in the UK, reduce variation and offer consistent care at the level we want everywhere, in the next 3 years. In July, 85% of 120 healthcare professionals agreed with this statement (‘Raising the Bar’,…
